摘要
目的观察参芪注射液在乳腺癌术后选择性靶向治疗中对提高疗效、改善生活质量及增加机体免疫力的作用。方法将52例乳腺癌患者随机分为2组,均予希罗达2 000mg/m2口服,每日1次,连服2周,休息1周,每3周为1个疗程。治疗组在每周期治疗之前给予参芪注射液250 mL静脉滴注,连用3 d。结果治疗后治疗组病情稳定率及生活质量、免疫功能改善情况均明显优于对照组(P均<0.05)。结论参芪注射液在乳腺癌术后选择性靶向治疗可增强机体免疫力,改善生活质量,提高病情稳定性。
Objective It is to observe the function of Shenqi injection on potentiation of curative effect, improvement of life quality and strengthening body immunity in the selectivity target therapy after breast carcinoma operation. Methods 52 patients with breast carcinoma were randomly divided into two groups. Both of the groups were treated with Xeloda 2 000 mg/m^2 by oral use once a day and for 2 weeks. After one week＇s rest, the treatment was continued. Every 3 weeks were one treatment course. The treatment group was given Shenqiqnjection 250 mL by intravenous drip for 3 days before every treatment stage. Results The stability rate of the disease and improvement of immunity in the treatment group were both better than that in the control group （P 〈 0.05）. Conclusion Shenqi injection can strengthen body immunity, improve life quality and increase stability of disease in the selectivity target therapy after breast carcinoma operation.
出处
《现代中西医结合杂志》
CAS
2010年第7期781-782,共2页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
河北省重点科技研究计划项目(20090695)
关键词
参芪注射液
乳腺癌
选择性靶向治疗
免疫功能
Shenqi injection
breast carcinoma
selectivity target therapy
immunity
